---
title: Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from
  an international panel on behalf of the EBMT
date: '2025-02-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39970324/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250220170938&v=2.18.0.post9+e462414
source: Blood
description: For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic
  hematopoietic cell transplantation (allo-HCT) represents the only potentially curative
  treatment, capable of eradicating disease-related mutant hematopoietic cells and
  establishing normal donor hematopoiesis. Biologic-assignment clinical trials have
  indicated that in eligible patients, allo-HCT is associated with superior clinical
  outcomes compared to non-transplant therapy. However, this therapeutic option is
  only ...
disable_comments: true
---
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes compared to non-transplant therapy. However, this therapeutic option is only ...